Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

About 1 in 5 patients with B-cell lymphoma treated with loncastuximab develop skin-related adverse events, particularly ...

Recombinant Hirudin (rH) inhibited the polarization of M2-type macrophages and protease-activated receptor-1 (PAR-1) in diffuse large B-cell lymphoma (DLBCL). A study of 32 clinical samples from ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

The trial aims to enrol nearly 200 patients per arm, including those with diffuse large B-cell lymphoma.

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...

XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for ...

– Application is based on data from the Phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival – – This ...

R CHOP re treatment offers durable responses in patients with late relapse diffuse large b cell lymphoma, with a 2-year time ...